Steven L Fasman Net Worth

Track Major Insider Updates On X/Twitter

Last Updated: 4 months, 4 weeks ago

Steven L Fasman has an estimated net worth of at least $11.0 million*, as of Dec. 11, 2024. They own 72,380 shares of CTLT stock. They have sold 55,574 shares of CTLT stock since 2021, for an estimated $6.5 million.

Steven L Fasman $CTLT SEC Form 4 Insider Trading

Steven L Fasman has filed a total of 14 insider trades in $CTLT since 2021. Their most recent trade was a sale of 817 shares, made on Aug 24, 2023. Their largest trade was a sale of 20,513 shares, made on Oct 04, 2021. We estimate that they now own 72,380 shares of $CTLT, worth an estimated $4.5 million.

Insider Trading at $CTLT

There have been a total of 137 insider trades reported at $CTLT since 2021, with 22,000 shares purchased and 3.9 million shares sold. The most active insider traders in $CTLT stock have been Michael J Grippo, Scott Gunther, and Steven L Fasman. The most recent trade was a sale of 2,800 shares reported by Michelle R Ryan (None), made on Nov 11, 2024.

History of Insider Stock Trades by Steven L Fasman

Company Ticker	Purchase / Sale	Shares	Date	Disclosed (EST)
CTLT	Sale	817	Aug 24, 2023	Aug. 25, 2023, 7:02 p.m.
CTLT	Sale	524	Aug 01, 2023	Aug. 3, 2023, 4:02 p.m.
CTLT	Sale	1,113	Aug 01, 2023	Aug. 3, 2023, 4:02 p.m.
CTLT	Sale	4,811	Aug 25, 2022	Aug. 26, 2022, 8:16 p.m.
CTLT	Sale	2,546	Jul 26, 2022	July 28, 2022, 7:42 p.m.
CTLT	Sale	3,049	Jun 10, 2022	June 13, 2022, 4:57 p.m.
CTLT	Sale	1,951	Jun 10, 2022	June 13, 2022, 4:57 p.m.
CTLT	Sale	8,209	Oct 04, 2021	Oct. 5, 2021, 8 p.m.
CTLT	Sale	4,192	Oct 04, 2021	Oct. 5, 2021, 8 p.m.
CTLT	Sale	20,513	Oct 04, 2021	Oct. 5, 2021, 8 p.m.
CTLT	Sale	1,800	Oct 04, 2021	Oct. 5, 2021, 8 p.m.
CTLT	Sale	1,549	Jul 26, 2021	July 27, 2021, 8 p.m.
CTLT	Sale	3,313	Jul 15, 2021	July 15, 2021, 8 p.m.
CTLT	Sale	1,187	Jul 15, 2021	July 15, 2021, 8 p.m.

$CTLT Executives and Stock Owners with Insider Trades

Michael J Grippo, SVP, Strategy & Corp. Dev.
Scott Gunther, SVP, Quality & Reg. Affairs
Steven L Fasman, SVP & General Counsel
John R Chiminski, Chair & CEO
Alessandro Maselli, President & CEO
Aristippos Gennadios, Group Pres. Pharma & Consumer
Steven L Fasman, EVP & Chief Admin Officer
Ricky Hopson, Pres. Clinical Dev Supply Div
Ricardo Pravda, SVP & Chief HR Officer
Lorenzo Carletti, SVP Global Ops Ph & Cons Hlth
Thomas P Castellano, SVP, Chief Financial Officer
Thomas W Hawkeswood, Pres. Pharma Prod Delivery Div
Patricia Hunt, Pres. Consumer Health Div
Ricky Hopson, Pres. BioProduct Delivery, CoS
Manja Boerman, Pres. BioModalities Division
Jonathan Arnold, Pres. Oral & Specialty Deliv.
Ricardo Pravda, Chief Transformation Officer
Michael A. Riley, Pres. Bio Product Delivery Div
Charles Lickfold, SVP, CIO
Ricky Hopson, VP, Chief Accounting Officer
John R Chiminski, Executive Chair
Ricky Hopson, Pres, Clinical Dev & Supply
Jonathan Arnold, SVP & Chief Commercial Ofcr
Joseph Anthony Ferraro, SVP, General Counsel, CCO
Jonathan Arnold, SVP, CCO & Div. Head BioP Del.
Kay A Schmidt, SVP, Technical Operations
Kay A Schmidt, SVP, Enterprise Functions
Mario Gargiulo, SVP Global Ops Biologics
Matti Masanovich, SVP, Chief Financial Officer
Karen Flynn, Chief Commercial Officer
Mario Gargiulo, SVP, Ops, Biologics Europe
Mario Gargiulo, SVP Global Ops Large Molecule
Ricci S Whitlow, President, CSS
Alessandro Maselli, President & COO
Lisa Evoli, SVP, Chief HR Officer
John J Greisch, Executive Chair
David Mcerlane, Group President, Biologics
Aristippos Gennadios, President Softgel & Oral Tech

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.